Interpace Diagnostics Faces Nasdaq Delisting

Nov 30, 2016

|

NEW YORK (GenomeWeb) – Interpace Diagnostics' stock faces delisting from the Nasdaq due to the company's failure to maintain a minimum of $2.5 million in stockholders' equity, according to a document filed yesterday with the US Securities and Exchange Commission.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Breaking News

Featured White Papers

A High-Performance Solution Combining CleanPlex OncoZoom Cancer Hotspot Panel and SOPHiA AI for Rapid Characterization of Somatic Mutations

Benchmarking of the Microsart AMP Mycoplasma Kit with Products of Two Other Suppliers

Type 1 Interferon Gene Expression Analysis: Precision Medicine in Lupus

Oct

24

Featured Webinar

Designing, Decoding & Delivering on Genetic Testing for Inherited Disease at Versiti

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

Nov

14

Featured Webinar

High-Performance Variant Detection in Somatic Cancer Testing with an Integrated NGS Solution

This webinar will discuss some of the issues laboratories face when transitioning to next-generation sequencing, and the key features to be considered for a successful implementation in routine testing.

Dec

02

Featured Webinar

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of   FLT3  and  CEBPA

This webinar will discuss how Moffitt Cancer Center  has implemented a new capture-based application to accurately assess myeloid malignancies  by detecting complex variants in challenging genes  in a single experiment. 

Menu